{"id":8754,"date":"2025-08-14T04:08:16","date_gmt":"2025-08-14T08:08:16","guid":{"rendered":"https:\/\/www.packagingindustrynews.com\/?p=8754"},"modified":"2025-08-14T04:08:16","modified_gmt":"2025-08-14T08:08:16","slug":"navamedic-gains-approval-for-flexilev-in-orafid-packaging-in-nordic-countries","status":"publish","type":"post","link":"https:\/\/www.packagingindustrynews.com\/?p=8754","title":{"rendered":"Navamedic gains approval for Flexilev in OraFID packaging in Nordic countries"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n \n <\/picture>
The dispenser is designed to provide precise and personalised treatment for patients. Credit: Mouse family\/Shutterstock.com.<\/figcaption><\/figure>\n<\/p><\/div>\n

Navamedic has secured final approval for the Flexilev\u00a0in OraFID tablet dispenser packaging material in the national languages of Norway, Sweden, and Denmark.<\/p>\n

OraFID is a patented, entirely mechanical medical device designed to deliver exact amounts of mini tablets to patients with a simple mechanism operated by a few twists of the hands.<\/p>\n

The company received the first approval of OraFID as the primary package for a pharmaceutical product in June 2025.<\/p>\n

The product licensor, Orion Corporation, has also received final confirmation for the Finnish market.<\/p>\n

Navamedic CEO Kathrine Gamborg Andreassen said: \u201cWe are excited to have received the last approvals, paving the way for our go-to-market launch in the Nordic region.\u201d<\/p>\n

The Flexilev in OraFID dispenser is designed to provide precise and personalised treatment for patients with Parkinson\u2019s, particularly advantageous for medications with a narrow therapeutic window.<\/p>\n

Hyper-fractionation, which involves administering smaller, more frequent doses, is made possible through this approach.<\/p>\n

Following the acquisition of Sensidose in May 2023, Flexilev, a novel prescription treatment for Parkinson\u2019s disease, became part of Navamedic\u2019s product range.<\/p>\n

The launch of OraFID in the Nordic markets is anticipated this October.<\/p>\n

Navamedic entered into a licensing and supply agreement with Orion for the distribution of Flexilev, which includes OraFID, across Europe in June 2024.<\/p>\n

This agreement excludes Sweden, Norway, Denmark, and Iceland, where Navamedic retains the rights to market and sell the product.<\/p>\n

Orion has secured the exclusive rights to market, distribute, and sell Flexilev in 27 European countries, including the five largest markets: Germany, France, Italy, Spain, and the UK.<\/p>\n

Orion acts as the marketing authorisation holder within its designated territory and will carry all associated rights and obligations.<\/p>\n

<\/p>\n

<\/p>\n

\n